<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779181</url>
  </required_header>
  <id_info>
    <org_study_id>ADX415-301</org_study_id>
    <nct_id>NCT00779181</nct_id>
  </id_info>
  <brief_title>A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension</brief_title>
  <official_title>A Phase 2, Dose-Ranging Study of the Safety and Efficacy of ADX415 Immediate-Release in the Treatment of Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addrenex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addrenex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine a safe and effective dose of ADX415 for the
      treatment of hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ABPM measures</measure>
    <time_frame>Baseline to Day 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events, lab tests, vitals signs, and ECGs</measure>
    <time_frame>Throughout treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>ADX415 (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of ADX415</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADX415 (mid level dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A mid level dose of ADX415</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADX415 (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of ADX415</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX415</intervention_name>
    <description>ADX415 taken three times a day to achieve a high total daily dose</description>
    <arm_group_label>ADX415 (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX415</intervention_name>
    <description>ADX415 taken three times a day to achieve a mid level total daily dose</description>
    <arm_group_label>ADX415 (mid level dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX415</intervention_name>
    <description>ADX415 taken three times a day to achieve a low total daily dose</description>
    <arm_group_label>ADX415 (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken three times a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate hypertension

          -  Age 18-75 years, inclusive

        Exclusion Criteria:

          -  Clinically significant illnesses or abnormalities upon evaluation

          -  Current treatment with 3 or more antihypertensive meds

          -  Presence of Type I or uncontrolled Type II diabetes

          -  Presence of alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moise Khayrallah, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Addrenex Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>December 16, 2008</last_update_submitted>
  <last_update_submitted_qc>December 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Moise Khayrallah, PhD / President and CEO</name_title>
    <organization>Addrenex Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>High blood pressure</keyword>
  <keyword>Htn</keyword>
  <keyword>Addrenex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

